Your average biotech isn’t trying to treat late stage cancer with encapsulated cells triggering chemotherapy to have maximum impact and minimum side effects.
That’s why we’re investing here.
It’s novel. It’s unique. It’s the future of medical delivery
If we wanted to invest in an ordinary biotech we’d choose another one.
We’ve chosen this one because it’s a game changer.
And that’s what we like about it. Stumbles, delays. Errors and all.